Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago Solid tumor

Hope to Eradicate Lung Cancer, Colorectal Cancer, and Various Solid Tumors! China’s First Self-Replicating mRNA Vaccine JCXH-211 Successfully Launched~

mRNA Vaccine

Tumor immunotherapy, as an emerging method for diagnosing and treating tumors, has garnered widespread attention since its inception. Prior to the advent of tumor immunotherapy, the clinical treatment of solid tumors relied solely on traditional surgical removal, radiotherapy, and chemotherapy. Although these methods were effective, they came with significant drawbacks such as drug side effects and the risk of recurrence.

Since the 1990s, mRNA vaccines have been considered therapeutic vaccines. During the COVID-19 pandemic in 2020, mRNA vaccines were used in clinical treatments, saving countless lives. Today, as the advantages of mRNA vaccines are gradually being discovered, they are now applied in multiple fields.

The advent of China’s first self-replicating mRNA vaccine JCXH-211 undoubtedly marks a new breakthrough in the clinical diagnosis and treatment of various solid tumors in China.

What is the mRNA Vaccine JCXH-211?

JCXH-211 is the world’s first self-replicating RNA drug encoding human interleukin-12 (IL-12) to enter clinical trials. This srRNA vaccine delivers mRNA encoding IL-12 into the cytoplasm, continuously expressing IL-12 to enhance the body’s immune response against tumor cells.

In preclinical studies involving various mouse and PDX disease models, JCXH-211 has shown the ability to effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. Comprehensive GLP toxicology studies have also demonstrated good safety.

JCXH-211 has a broad range of indications and is expected to effectively treat multiple solid tumors. The anticipated prospects are as follows:

1. Lung Cancer:

As one of the leading causes of cancer death worldwide, lung cancer is often diagnosed at a late stage due to difficulties in early detection. JCXH-211, through continuous expression of IL-12 and activation of immune cells, is expected to effectively control the growth and spread of lung cancer cells.

2. Colorectal Cancer:

Current clinical treatments for colorectal cancer primarily involve surgery and radiotherapy/chemotherapy, which can remove visible tumors but have a high recurrence rate. Periodic administration of JCXH-211 may significantly reduce recurrence and improve patient survival.

3. Soft Tissue/Chondrosarcoma:

These tumors are highly invasive and cover a wide range of areas, often affecting surrounding soft tissues and progressing rapidly. Current treatments are limited to surgery and radiotherapy/chemotherapy, which, although somewhat effective, are not thorough, leading to high recurrence rates. JCXH-211 could become a new treatment method, enhancing the body’s immune response to combat these stubborn cancer cells.

4. Skin Cancer:

Clinical treatments for skin cancer mainly include surgery and radiotherapy. While most skin cancers have a good prognosis, the effects on intractable melanoma are poor. The expression of IL-12 can activate specific T cells, greatly aiding in the elimination of melanoma cells.

High-Efficiency Activation and Safety of the mRNA Vaccine JCXH-211!

mRNA vaccines not only encode antigens to induce specific immune responses against tumors but also possess inherent immunostimulatory properties. This dual mechanism allows JCXH-211 to activate the immune system more efficiently, enhancing the overall anti-tumor effect.

Moreover, the safety of mRNA vaccines is well-recognized. Since DNA is the genetic material of most species, including humans and viruses, and is transcribed into mRNA before being translated into proteins to perform functions in the body, injecting mRNA into the human body does not enter the cell nucleus, thereby eliminating the risk of genomic insertion mutations. Additionally, mRNA can be naturally degraded and excreted from the body, preventing accumulation. Thus, JCXH-211 presents lower potential risks and is safer.

Currently, clinical trials are progressing steadily. With the rapid advancement of tumor immunotherapy, JCXH-211 is expected to become a standard treatment for various solid tumors, offering hope to many cancer patients.

To assess whether the condition is suitable for cancer vaccine or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

8 months ago CAR-T

🎉 #PNAS Breaking News: Revolutionary CAR-T Cell Therapy Successfully Treats Autoimmune Disease in China! 🎉

PNAS

In a groundbreaking development, Chinese medical experts have achieved a milestone in the treatment of autoimmune diseases using CAR-T cell therapy.

🩺 A New Hope for Autoimmune Diseases

Autoimmune-mediated necrotizing myopathy (#IMNM) poses a significant challenge in clinical management due to its severe symptoms and limited efficacy of traditional pharmacological approaches. However, a ray of hope emerges with the application of Chimeric Antigen Receptor (CAR) T-cell therapy targeting B cell maturation antigen (#BCMA).

🔬 The Breakthrough Study

Published in the prestigious #journal PNAS, the study titled “Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy” by the medical team at Huazhong University of Science and Technology sheds light on a remarkable case. A patient with anti-signal recognition particle (SRP) IMNM exhibited significant improvement in clinical symptoms and sustained reduction in pathogenic autoantibodies after receiving BCMA-targeted CAR-T cell therapy for over 18 months.

🧬 Understanding the Mechanisms

Through longitudinal single-cell RNA sequencing and analysis of T cell receptors and B cell receptors, researchers elucidated the normalization of the immune microenvironment post-CAR-T cell infusion. The expansion of CD8+ CAR-T cells, coupled with dynamic phenotypic transitions in both CD4+ and CD8+ CAR-T cells, was observed, indicating a promising avenue for the treatment of autoimmune diseases.

🔍 Implications for the Future

This study not only highlights the efficacy of CAR-T cell therapy in refractory IMNM but also underscores the importance of understanding the molecular characteristics of CAR-T cells in autoimmune diseases. Further research is warranted to enhance the efficiency and durability of CAR-T cell therapy for autoimmune conditions.

🌟 Hope for Patients Worldwide

With this groundbreaking achievement, there is renewed hope for millions of individuals battling autoimmune diseases globally. Stay tuned for more updates as we continue to unlock the potential of innovative therapies in medical science!

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

#CAR_TTherapy #AutoimmuneDisease #MedicalBreakthrough #Science #Innovation #PNAS #cart #cartcell #BCMA #IMNM #chineseresearch #medicalscience

9 months ago CAR-T

Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements

🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬

Patient 1: 53-year-old Male

Gastric Cancer,
Pancreatic Cancer

Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by nearly 50%, achieving sustained remission for 32 weeks.

Patient 2: 57-year-old Female

Gastric Cancer,
Pancreatic Cancer

Gastric cancer with peritoneal metastasis and Sister Mary Joseph’s nodule (malignant tumor metastasis forming a nodule-like lesion in the umbilicus). Previously received third-line therapy including PD-1 antibodies, CLDN18.2 expression 80% (2+). Achieved partial remission after CAR-T therapy, with sustained response exceeding 56 weeks.

🏆 CT041 Achievements 🏆

– In May 2020, FDA approved CT041 for investigational new drug (IND) authorization for the treatment of claudin18.2-positive gastric, gastroesophageal junction, or pancreatic adenocarcinoma patients.

– In 2020, received orphan drug designation from the U.S. FDA for the treatment of gastric/gastroesophageal junction cancer.

– In 2021, granted orphan drug designation by the European Medicines Agency (EMA) and qualified for the European PRIME program.

– In 2022, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.

– On March 3, 2022, approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to enter Phase II clinical trials!

We are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

doctor.huang@globecancer.com,

or WhatsApp+8613717959070

The Medical Department will contact you as soon as they receive the reports.

#CancerResearch #Immunotherapy #CART #MedicalBreakthrough #ClinicalTrials #FDAApproval #OrphanDrug #HealthcareInnovation #GastricCancer #PancreaticCancer #CT041 #MedicalAdvancement #RegenerativeMedicine #RMAT #EMAApproval #NMPAApproval #MedicalScience #PrecisionMedicine #PatientCare

10 months ago CAR-T

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 Haematologica Spotlight 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and extramedullary sites. While the prognosis for childhood ALL is relatively favorable, with a 5-year overall survival rate of 80-90%, adult ALL poses greater challenges. Approximately 20-30% of adult acute leukemias are ALL, with about two-thirds being Philadelphia chromosome-negative (Ph-negative) ALL. Conventional adult ALL treatments have shown high remission rates but also high relapse rates and poor long-term survival.

Haematologica

Inspired by the success of pediatric ALL treatments, especially in adolescent and young adult patients, the Hematology Center at the

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

embarked on a groundbreaking journey. Their pioneering research, recently published in *Haematologica*, presents the results of the largest prospective cohort study in China investigating the efficacy of a pediatric-inspired regimen in adult Ph-negative ALL patients.

The study, led by Dr. Wang Jianxiang and his team,

evaluated the IH-2014 regimen’s effectiveness in 415 newly diagnosed adult Ph-negative ALL patients treated between April 2014 and December 2021, with a median age of 27 years (range 14-65 years) and a median follow-up of 40.8 months. The overall 5-year overall survival (OS) and disease-free survival (DFS) rates were 53.8% and 51.1%, respectively, with a chemotherapy-related mortality rate of 3.6%.

Patients achieving complete remission (CR)

after induction therapy with available bone marrow minimal residual disease (MRD) data were categorized based on diagnostic risk: standard-risk (SR) MRD-negative (<0.01%) in 73 patients (18.8%), SR MRD-positive (≥0.01%) in 69 patients (17.7%), high-risk (HR) MRD-negative in 120 patients (30.8%), and HR MRD-positive in 127 patients (32.6%). The 5-year OS rates for these groups were 82.6%, 58.7%, 58.3%, and 36.1%, respectively (P＜0.001), with corresponding cumulative relapse rates of 24.2%, 41.1%, 36.3%, and 50.1% (P＜0.001). Multivariate analysis identified age ≥40 years and MRD positivity after induction as independent adverse prognostic factors for OS and DFS.

In conclusion, the IH-2014 regimen demonstrates significant efficacy and good tolerability in adult Ph-negative ALL patients, with younger patients (<40 years) benefiting more prominently. Induction treatment response combined with MRD levels serves as a valuable prognostic indicator for long-term survival and relapse, guiding allogeneic hematopoietic stem cell transplantation decisions in patients achieving first complete remission (CR1).

This study marks a pivotal milestone in advancing adult ALL treatment strategies, showcasing China’s remarkable progress in the field of hematology. Stay tuned for more groundbreaking research from our team!

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

🌟 #Haematologica #LeukemiaTreatment #PediatricInspiration #ALL #AcuteLymphoblasticLeukemia #LymphoblasticLeukemia #Leukemia

10 months ago CAR-T

Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma!

🌟 Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma! 🌟

synovial sarcoma

“Engineered T Cell Receptor-T Cell Therapy,” or “TCR-T (engineered T cell receptor-T cell, TCR-T) cell therapy,” involves the extraction of peripheral blood mononuclear cell (PBMC) samples from patients, followed by genetic engineering to introduce selected high-affinity T cell receptors (TCRs) into T cells. This enables them to seek out and specifically recognize tumor antigens, effectively targeting and killing cancer cells.

In early 2022, the Food and Drug Administration (FDA) in the United States approved a TCR-T therapy called “Kimmtrack” for treating uveal melanoma, marking a significant milestone in solid tumor treatment.

Recently, the prestigious international journal “Cell Rep Med” reported the Phase I clinical trial results of China’s first investigational new drug (IND) approved by the FDA for TCR-T cell therapy — TAEST16001. This groundbreaking research represents a crucial step forward in the clinical translation of adoptive T cell immunotherapy for advanced soft tissue sarcoma and holds the potential to become the world’s second marketed TCR-T cell therapy targeting solid tumors!

Cell Rep Med

China’s first TCR-T product IND approval takes aim at synovial sarcoma.

TAEST16001,

developed independently by Xiangxue Life Sciences, is a TCR-T cell product. The Phase I clinical trial enrolled 12 patients with advanced soft tissue sarcomas who were HLA-A*02:01 positive and expressed the NY-ESO-1 antigen. Among them, 10 patients had synovial sarcoma, while 2 had liposarcoma (1 myxoid liposarcoma and 1 dedifferentiated liposarcoma), with a median age of 33 (25-67) years. 58.3% (7/12) of patients were male. Before enrollment, 83.3% of patients had received at least two types of chemotherapy. After enrollment, all patients underwent modified lymphocyte clearance surgery followed by infusion treatment with TAEST16001 cells.

After a median treatment duration of 43 days, 9 out of 12 patients (75%) showed tumor regression (Figure 1), with a median time to response (TTR) of 1.9 months and a median duration of response of 13.1 months. Six patients (50%) exhibited sustained tumor burden reduction after the first radiological assessment. In the primary analysis, 5 out of 12 patients achieved partial responses, resulting in an objective response rate (ORR) of 41.7% (95% CI, 15.2–72.3). Disease stabilization was observed in 5 cases [41.7% (95% CI, 15.2–72.3)], yielding a disease control rate of 83.3% (95% CI, 51.6–97.9). The median progression-free survival (PFS) was 7.2 months (95% CI, 2.5–11.8).

TCR-T Therapy

How to Seek TCR-T Therapy Assistance

Several TCR-T therapies under development in China are urgently recruiting patients with hepatitis B virus-related liver hepatocellular carcinoma, head and neck tumors (oral cancer, laryngeal cancer, etc.), advanced cervical cancer, and anal cancer.

If you wish to assess whether your condition is suitable for CAR-T therapy, you can submit your pathological reports, treatment history, and discharge summaries to

<Advanced Medicine in China> doctor.huang@globecancer.com for preliminary evaluation.

or click on the WhatsApp+8613717959070

Stay tuned for more updates on this groundbreaking advancement in cancer treatment! 🌟

#CancerResearch #TCRTtherapy #SynovialSarcoma #MedicalInnovation

10 months ago CAR-T

Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.

🌟 Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.🌟

cervical cancer

🏥💊（Jiangsu Hengrui Pharmaceuticals Co., Ltd）Hengrui Pharmaceutical’s PD-L1 inhibitor Atezolizumab injection combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer has been approved for open, multicenter Phase II clinical trials.

Atezolizumab

🌸🎀#Cervical cancer is the fourth most common cancer in women globally, mainly caused by persistent infection with high-risk human papillomavirus (#HPV). Although the widespread implementation of #cervicalcancer screening and the availability of HPV vaccines have reduced the incidence of cervical cancer in developed countries, it remains one of the common malignant tumors in women.

🏥💊Atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Medicine. It is the first PD-L1 inhibitor approved for the treatment of small cell lung cancer in China. By specifically binding to the PD-L1 molecule, it blocks the PD-1/PD-L1 pathway that leads to tumor immune tolerance, reactivating the immune system’s anti-tumor activity and achieving the goal of tumor treatment.

The Lancet Oncology

🌸🎀Atezolizumab injection has been studied in various fields, including small cell lung cancer, #NSCLC non-small cell lung cancer, esophageal cancer, liver cancer, and cervical cancer. It has shown promising efficacy in small cell lung cancer. Based on the results of the SHR-1316-III-301 study, the application for the market approval of Atezolizumab injection combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer has been accepted and approved in China in March 2023. The study results have been published in the top international medical journal “The Lancet Oncology,” and the original research from China has been internationally recognized.

🏢💊Jiangsu Hengrui Pharmaceuticals Co., Ltd is committed to advancing the clinical research of the PD-L1 inhibitor Atezolizumab injection, bringing more innovative and effective treatment options for cervical cancer patients. Stay tuned for our progress!

Hengrui Pharmaceutical

🚑In addition to Cervical cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the 📩email address: doctor.huang@globecancer.com📩, or click on the ✉️WhatsApp+8613717959070✉️ icon on the homepage. The Medical Department will contact you as soon as they receive the reports.

#CervicalCancerTreatment #Atezolizumab #HengruiMedicine #ClinicalTrials #CancerTreatment #cervical #cervicalcancer #chinesemedicine #newdrug #Lancet #TheLancetOncology

📩References：　　

[1]gco.iarc.fr(WHO statistics)

　　[2]Rose PG,Bundy BN,Watkins EB,Thigpen JT,Deppe G,Maiman MA,Clarke-Pearson DL,Insalaco S:Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med1999,340(15):1144-1153.

　　[3]Pfaendler KS,Tewari KS:Changing paradigms in the systemic treatment of advanced cervical cancer.Am J Obstet Gynecol2016,214(1):22-30.

　　[4]Liu C,Lu J,Tian H,Du W,Zhao L,Feng J,Yuan D,Li Z:Increased expression of PDL1by the human papillomavirus16E7oncoprotein inhibits anticancer immunity.Mol Med Rep2017,15(3):1063-1070.

10 months ago CAR-T

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6%

Meet Sunvozertinib, the game-changer in advanced lung cancer therapy!

Sunvozertinib, NSCLC

This groundbreaking oral medication, a novel irreversible EGFR-TKI, targets multiple EGFR mutation subtypes with remarkable precision. What’s more? Sunvozertinib is now the FIRST and ONLY EGFR-TKI approved for treating late-stage NSCLC with EGFR exon20ins mutations!

At the 2023 ESMO Conference, fresh data from early trials of Sunvozertinib’s frontline treatment for EGFR exon20ins-mutated advanced NSCLC were unveiled, and the results were jaw-dropping!

With an astounding Objective Response Rate (ORR) of 78.6% and a median Progression-Free Survival (PFS) of 12.4 months at the recommended dose (300mg QD), Sunvozertinib once again set a new benchmark in this field, offering a superior treatment option for newly diagnosed patients with EGFR exon20ins mutations!

Let’s dive into a real success story: A 35-year-old male diagnosed with late-stage NSCLC harboring EGFR exon20ins mutations, along with metastases to the brain, liver, and bones. After showing stable disease (SD) following two cycles of platinum-based chemotherapy, he switched to Sunvozertinib. Just one month into treatment, a follow-up chest CT scan revealed a remarkable 34% reduction in the size of the left lower lobe lesion, with lung lesions shrinking from 29mm×26mm to 19mm×15mm (see image). Multiple nodules in the lungs and pleura also decreased in size, along with liver lesions. Evaluation: Partial Response (PR)!

Lung Cancer

Noteworthy is the impeccable safety profile of Sunvozertinib, with no significant adverse effects reported during treatment. As of this post, the patient continues to receive Sunvozertinib monotherapy with promising outcomes!

With breakthroughs in targeted therapies for EGFR exon20ins-mutated NSCLC, several new drugs are actively exploring frontline treatment options. The early study results of Sunvozertinib’s frontline therapy for EGFR exon20ins-mutated advanced NSCLC have once again rewritten the records in this field, providing new treatment guidelines for these patients!

#LungCancerAwareness #Sunvozertinib #EGFRexon20ins #NSCLC #TargetedTherapy #MedicalBreakthroughs #HealthcareInnovation #lungs #lung #lungcancer #chinesemedicine #EGFR

10 months ago CAR-T

Revolutionizing Medicine: CAR-T Therapy Beyond Cancer

🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀

🔬 Over the past decade, CAR-T cell therapy has transformed the field of oncology, successfully treating previously incurable blood cancers. While CAR-T therapy gained fame for its success in cancer treatment, the roots of this groundbreaking principle trace back nearly 30 years—initially exploring T cell therapy for HIV/AIDS. Although the early attempts didn’t succeed in treating HIV/AIDS, they demonstrated the enduring potential of engineered T cells in immunocompromised patients.

🌟 CAR-T therapy, or Chimeric Antigen Receptor T-cell Immunotherapy, essentially involves reengineering a patient’s immune T cells outside the body to recognize antigens on the surface of tumor cells. These modified cells are then reintroduced into the patient, effectively identifying and eliminating cancer cells. Scientists have been tirelessly working to extend CAR-T therapy beyond blood cancers to various other types.

💡 Moreover, research from both clinical and preclinical studies indicates that CAR-T therapy holds great promise beyond cancer treatment. It shows potential applications in autoimmune diseases, chronic infections, heart diseases, aging-related conditions, and more.

🌐 In recent years, scientists have focused on applying CAR-T therapy to solid tumors, exploring its potential in cancer types beyond blood-related malignancies. Early research results suggest that the next frontier for CAR-T therapy may extend to various fields outside cancer, including autoimmune diseases (systemic lupus erythematosus, pemphigus vulgaris, multiple sclerosis, type 1 diabetes, asthma), fibrotic diseases (fibrosis in the heart, liver, lungs, and kidneys), aging-related conditions (liver fibrosis, solid tumors, atherosclerosis, natural aging), and infectious diseases (HIV/AIDS, hepatitis B and C, pulmonary tuberculosis).

🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground

#immunotherapyrevolution #CARTTherapy #MedicalInnovation #BeyondCancer #ImmunotherapyRevolution #CART #cancer #tumor #cancertreatment #tcell

10 months ago CAR-T

Exciting breakthrough in Chinese pharmaceutical research!

[🔬🌏] Exciting breakthrough in Chinese pharmaceutical research!

Chinese medicial research

💊Since 2019, China has witnessed a surge in phase 1 and 2 clinical trials, with a focus on addressing prevalent cancers like stomach, esophageal, and cervical cancers. The world is now turning its attention to China’s rapid emergence on the global stage of pharmaceutical innovation.

🌟 Key Highlights:

PD-1, PD-L1, VEGFR, EGFR, and HER2 are at the forefront of Chinese drug development.

PD-1/PD-L1 therapies have shown outstanding efficacy in Asian patients, gaining approvals for various cancer treatments. The influx of these therapies has increased accessibility to cancer immunotherapy, simultaneously driving market competition and reducing economic burdens for patients and healthcare systems.

🚀 2020 and Beyond:

Rapid growth in the development of VEGFR, EGFR, and HER2 pathways. The approval of AK104, a dual-specificity PD-1/CTLA-4 antibody for cervical cancer treatment, marks a milestone.

Innovative discoveries in clinical research for gastrointestinal tumor drug targets like CLDN18.2, including CLDN18.2–CD3, CLDN18.2–PD-L1, and CLDN18.2 antibody-drug conjugates, promise a bright future for cancer treatments.

🌿 Traditional Medicine Meets Innovation:

Local biopharmaceutical companies in China are shifting towards “First in Class.” FDA and NMPA approvals for novel drugs like PRJ1-3024, ORIN001, and JS004 showcase this shift.

Traditional Chinese Medicine (TCM) continues to play a vital role in oncology, with formulations like As2O3 displaying potent anti-tumor activity. TCM is gaining attention, actively researching and revealing its anti-cancer mechanisms.

🔍 Future of Cellular Therapy:

While most studies focus on hematologic cancers, China’s research on solid tumor cellular therapy is rapidly expanding.

Diverse targets in solid tumors (gastric, lung, and neural) include MSLN, GPC3, MUC1, and CLDN18.2.

China’s forefront research in cellular therapy faces challenges but remains promising. With more efforts and innovations, the hope is for more effective solid tumor treatments in the future.

🌐 #ChinaMedicalInnovation #DrugDevelopment #CancerTreatment #CellularTherapy #medicalresearch

10 months ago CAR-T

Breakthrough Ultra CAR-T Therapy Shows High Disease Control Rate of 85.7% in Advanced Platinum-Resistant Ovarian Cancer

Breakthrough Ultra CAR-T Therapy Shows High Disease Control Rate of 85.7% in Advanced Platinum-Resistant Ovarian Cancer

As a skilled overseas social media writer, here’s a revamped article for international media promotion:

In a groundbreaking development, PRGN-3005, an Ultra CAR-T cell therapy, is making waves with an impressive disease control rate (DCR) of 85.7% in the treatment of advanced platinum-resistant ovarian cancer. Utilizing non-viral gene delivery technology, this therapy eliminates the need for ex vivo expansion, significantly reducing production time and costs. The ability to administer the treatment rapidly, as soon as the second day after non-viral gene transfer, not only lowers production time and costs but also enhances tumor targeting precision. This holds the potential to disrupt the current landscape of CAR-T cell therapy.

Published in the Journal of Clinical Oncology, the “Phase 1/1b Clinical Trial of PRGN-3005 in Recurrent or Refractory (r/r) Ovarian Cancer” reported promising outcomes. The study included 25 assessable patients with a median age of 64 (range: 38-76) who had undergone extensive pretreatment with a median of 8 prior therapeutic regimens. The patients were divided into three groups: intraperitoneal (IP) infusion (C1, n = 12), intravenous (IV) infusion (C2, n = 6), and intravenous cyclophosphamide low dose (IV LD, n = 7).

Post-treatment, 20% of all participants exhibited regression in at least one target lesion (evaluated by RECIST 1.1 criteria). Notably, the DCR for the IV LD group was an impressive 85.7%, with a 57% reduction in target tumor burden and an average 27.4% decrease in CA125. A patient in the IV LD group experienced a 28% reduction in target tumor burden after a second PRGN-3005 infusion at the 12-month mark. Importantly, no PRGN-3005-related dose-limiting toxicities, neurotoxicities, or ≥3-grade cytokine release syndrome (CRS) adverse reactions were observed.

These results underscore the favorable tolerability of PRGN-3005 Ultra CAR-T therapy in treating ovarian cancer, demonstrating an encouraging disease control rate (DCR) and an overall reduction in tumor burden.

While CAR-T therapy has shown great promise in treating hematologic malignancies and several products have been approved, its application in solid tumor treatment is still in the clinical experimental stage. Nevertheless, with the continuous evolution of CAR-T generations, the emergence of more prominent targets, and improvements in proliferation and cytokine release aspects, the conquest of advanced solid tumors by CAR-T therapy seems imminent. Numerous clinical trials are already underway, offering hope for complete remission in fortunate patients.

#PRGN3005 #CARTTherapy #OvarianCancer #MedicalBreakthrough #CancerTreatment #Ovarian

11 months ago CAR-T

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

Breakthrough CAR-T Cell Therapy for R/R B-Cell ALL: A Game-Changer in Chinese Medical Innovation

ALL- Acute Lymphoblastic Leukemia

The Fourth China Hematology Development Conference – CAR-T Frontier Forum and the First CAR-T Cell Immunotherapy Summit (JCIS), held on January 5, 2024, in Tianjin.

Potential Best-in-Class: Inaticabtagene Autoleucel Redefining Long-term Outcomes for R/R B-ALL

Professor Ma Jun from the Harbin Institute of Hematology and Oncology shared notable progress in immunotherapy and cell treatment for Chinese ALL. Previously, the overall complete response (CR) rate for adult R/R ALL treatment in China was approximately 40%, with a mere 11% 3-year survival rate. The introduction of CAR-T cell therapy has been a paradigm shift, altering the long-term outcomes for R/R B-ALL patients.

Inaticabtagene Autoleucel demonstrates superior efficacy:

Higher overall response rates (ORR) at 3 months and beyond, with median duration of response (DOR) and overall survival (OS) surpassing other products.

Patients treated with Inaticabtagene Autoleucel exhibit similar long-term benefits in OS, whether or not they undergo subsequent transplantation.

Inaticabtagene Autoleucel boasts enhanced safety:

Lower incidence rates of grade 3 cytokine release syndrome (CRS), grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS), and infusion-related mortality compared to other CAR-T products.

Moreover, in minimal residual disease-positive (MRD+) B-ALL patients, CAR-T cell therapy has shown significant progress. It eradicates MRD, improves survival rates, and may serve as a first-line consolidation therapy for CR patients, aiding in:

Higher remission rates

Reduced transplant requirements, mitigating transplant-related complications

Maintenance of long-term remission for those unsuitable for allo-HSCT or unwilling to undergo it

Improved overall survival

Lower intensity and duration of intensive chemotherapy, leading to shorter treatment times and enhanced compliance.

The Future Outlook: Believing in the potential of CAR-T cell therapy, it is anticipated that this innovative treatment will extend hope to currently incurable diseases such as solid tumors and brain tumors. The strides made in Chinese medical innovation, exemplified by Inaticabtagene Autoleucel, signal a promising future for the global landscape of CAR-T cell therapy.

#CARTRevolution #InaticabtageneAutoleucel #HematologicCancerTherapy #ClinicalBreakthrough #ChinaHematologyConference #JCIS #BAllTreatment #MedicalAdvancements #CancerResearch #TreatmentInnovation #InaticabtageneAutoleucel #Autoleucel #ChineseCART #CARTTherapy #cancer #Bloodcancer #MedicineinCHINA #Medicaltourismo #Advancedmedicine #cancertherapy #leukemia

11 months ago CAR-T

Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML

A recent clinical trial has unveiled a new prospect for treating relapsed/refractory acute myeloid leukemia (AML). The study delved into the safety and efficacy of a natural selection CD7 CAR-T cell (NS7 CAR-T cell) in treating CD7+ relapsed/refractory AML patients.

The research involved 10 cases of CD7+ relapsed/refractory AML, where 30% of AML patients expressed CD7. Following treatment with NS7 CAR-T cell infusion, the results showed that within 4 weeks post-infusion, 70% of patients achieved complete bone marrow remission (CR), with 6 patients achieving a deep remission at the level of minimal residual disease (MRD). Notably, the loss of CD7 was identified as a primary reason for non-response in some patients.

The study also indicated that the majority of patients (80%) experienced mild cytokine release syndrome (CRS) post-infusion, with no observed neurotoxicity.

Furthermore, for select patients, continuing with a second allogeneic hematopoietic stem cell transplantation post NS7 CAR-T cell treatment resulted in promising long-term outcomes. However, further exploration is required for patients who did not undergo consolidative transplants to enhance treatment efficacy.

Professor Lu Peihua(Lu Daopei Hospital) remarked that this study highlights the potential of CD7 CAR-T cells as a bridging therapy before transplantation, demonstrating preliminary therapeutic efficacy for relapsed/refractory AML patients. Nevertheless, a comprehensive evaluation of its efficacy requires a larger sample size and longer-term follow-up.

This preliminary study represents a significant advancement in the field of AML treatment, but collaborative efforts and more research are still necessary. Looking ahead, we anticipate further studies and treatment outcomes to bring more beneficial therapeutic options for the long-term survival of patients, supported by a broader patient cohort and collaborative efforts from the medical community.

The outlook for this CD7 CAR-T cell therapy is promising, especially for AML patients who have undergone various treatments and allogeneic hematopoietic stem cell transplants. We look forward to more in-depth research and treatment outcomes in the future, offering more beneficial treatment choices for long-term survival among patients.

(source: ClinicalTrials.gov registration number NCT04938115

Preliminary results published by Professor Lu Peihua and their team in a top-tier journal)

#AMLResearch #CancerTreatment #CARTTherapy #Leukemia #MedicalBreakthrough #Cancer #AML #Immunotherapy #ClinicalTrials #BloodCancer #PatientCare #HealthcareAdvances #PrecisionMedicine #ScienceAndHealth #MedicalScience #CancerSurvivor #AMLWarriors #ResearchProgress #CancerFree #HopeInTreatment #acutemyeloidleukemia

Menu

Tags Archives: Medical Science